Drugs / CoV2 SAM (LNP)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04758962 | Feb → Jun 2021 | viral infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CoV2 SAM (LNP) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04758962 ↗ |
| Known as | SARS-CoV-2 SAM (LNP) vaccine candidate | “Therefore, the SARS-CoV-2 SAM (LNP) vaccine candidate has a favorable safety profile, elicits robust protective immune responses against multiple SARS-CoV-2 variants, and has...” PMID 34990810 ↗ Jan 2022 |
| Modality | Messenger RNA (mRNA) | “self-amplifying messenger RNA (SAM) vaccine” PMID 34990810 ↗ Jan 2022 |
| Route | Intramuscular | “administered IM in the deltoid of the non-dominant arm” NCT04758962 ↗ |